Mark Smith, Finch Therapeutics CEO
Takeda breaks off five-year pact with microbiome partner, handing back two preclinical drugs
When Takeda first partnered up with Finch Therapeutics in 2017, the Japanese pharma put on the map what was still a very early-stage microbiome …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
